What is the problem with Bayer Trasylol (Bayer aprotinin)?
Two non-profit biomedical research organizations conducted the independent
observational study ("Trasylol Bayer report"). The organizations dedicated to saving and extending lives
are Ischemia Research and Education Foundation and the McSPI Research Group.
Principal scientist, Dennis T. Mangano, Ph.D., M.D., advocates that the "Trasylol Bayer report" provides compelling evidence of Bayer aprotinin's risks and strongly suggests
discontinuing use. He recommends replacing Bayer aprotinin with two alternative
generic drugs that are far less costly, much safer but for some reason marketed
less. Raising more concerns aprotinin has been on the market three times longer
than Vioxx exposing patients to life-threatening complications.
According to the study that examined 4,374 coronary artery bypass surgery patients at
hospitals around the world, replacing Bayer aprotinin with one of two safe generic
drugs would annually:
Prevent as many as 11,050 dialysis complications
Save at least $1 billion in healthcare (dialysis) costs
Reduce drug costs by at least $250 million
Interestingly enough the coronary artery bypass surgery drug with the most life-threatening
complications -- Bayer Trasylol -- costs $1,300 per dose. While the much safer generic
drugs cost unbelievably lower: Amicar costs only $11 per dose and Cyklokapron
costs $44 per dose. It's no small wonder that health insurance is so expensive!
Dr. Mangano estimates that as many as 10,000 patients
may be unnecessarily on dialysis today due to Bayer Aprotinin use.
Statistics show that each year approximately one million patients worldwide
undergo surgical treatment following a heart attack -- with the majority of
these patients receiving one of three antifibrinolytic agents to limit blood
loss during surgery: aprotinin, or one of the generic drugs. The two generic
drugs have proven safe in limiting blood loss and do not have the harmful
Bayer aprotinin side effects.
Personal Injury Disclaimer: This website provides general information about Pennsylvania Trasylol lawsuits and other legal information. Nothing on this site is intended to be legal advice. The materials on this site may be considered advertising. Nothing on this site constitutes the formation of an attorney client relationship. This website is not intended to solicit clients outside the State of New Jersey or the Commonwealth of Pennsylvania. In order to discuss representation, we must personally speak with you and enter into a signed, written agreement for representation. By utilizing this site, you agree to the foregoing.